PROVIDER PROFILE · NPI 1063828291

Sterling Fenwick

PRESCRIBING · PART D · 2024
Total Rx claims
28
Beneficiaries
Total drug cost
$254
Distinct drugs
2
Brand share
0.0%
Top prescribed drugs
Cefdinir12 claims
QUALITY · MIPS · 2024
Final MIPS score
80.8
Quality
72.8
Cost
63.1
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.24%
Group